Dyslipidemia in HIV patients
Marisa Tungsiripat, MD
Department of Infectious Diseases, The Cleveland Clinic Foundation
Judith A. Aberg, MD
Associate Professor of Medicine, Director of HIV, Bellevue Hospital Center, Director of AIDS Clinical Trials Unit, New York University
Address: Marisa Tungsiripat, MD, Department of Infectious Diseases, S32, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; email@example.com
Dr. Aberg has indicated that she is a consultant for Bristol-Myers Squibb, Boehringer-Ingelheim, Gilead Sciences, and Glaxo-SmithKline. She received research support from Bristol-Myers Squibb, Abbott, and Merck and is active in the leadership for the National Institute of Allergy and Infectious Diseases-sponsored AIDS Clinical Trials Group.
ABSTRACTThanks to antiretroviral therapy, people with human immunodeficiency virus (HIV) infection are living longer, but as they do, non-HIV medical problems become more relevant. In particular, dyslipidemia, an important reversible risk factor for cardiovascular disease, has been linked to HIV infection and its treatment. Although controversy remains as to whether people with HIV infections will develop premature coronary heart disease, it seems prudent to manage dyslipidemia in these patients just as we do in our HIV-negative patients. Interactions between lipid-lowering drugs and antiretroviral drugs require special attention.